We discuss the 2024 VPAG agreement, how it differs from the previous VPAS and whether this will impa...
Read moreWebinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (...
Read moreWe examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...
Read moreOur analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...
Read moreThe World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...
Read moreThis expert article focusses on the new proportionate approach, and the international recognition pr...
Read moreWe're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...
Read moreWebinar: Our experts discuss NICE's proportionate approach to technology appraisals and the implicat...
Read moreOur study aims to understand how the severity modifier has been implemented so far and its impact on...
Read moreLearn about the ground breaking consultation by NHS England and NICE on expanding the Antimicrobial ...
Read more